CVP focuses on assisting technology entrepreneurs achieve commercial success, particularly those facing the challenges of exponential growth. Holtz will also serve on the AzarGen scientific advisory board.ĭavid Murray is a director of Cape Venture Partners (CVP), a position he has held for the last 10 years. Holtz will provide research management services to AzarGen including: regulatory affairs planning and execution, and assistance in CMO management and technology transfer. He was awarded the Pennsylvania State University, Outstanding Alumni Award in 2003. patents and has published more than 50 scientific papers. at Pennsylvania State University and was an NSF Postdoctoral Fellow at Scripps Institution of Oceanography. Holtz has held research management positions at Foremost-McKesson and was on the faculty of Ohio State University. Holtz was responsible for the product development, long-term regulatory strategy, and clinical development and manufacturing compliance of the company’s proprietary therapeutics portfolio. Holtz was the Senior Vice President of Biopharmaceutical Development for Large Scale Biology Corporation (LSBC) for 15 years and was an integral member of the management team that successfully took the company from a start-up to a publicly-traded company. Holtz was the Co-Founder of G-CON Manufacturing, maker of autonomous cleanrooms and Caliber Biotherapeutics, developer and manufacturer of plant-made biotherapeutics. He has extensive expertise in providing consulting services to the biopharmaceutical development and manufacturing industry including facilities design, process development and quality systems development. Holtz is now the principal consultant at Holtz Biopharma Consulting, a founding member of the Klyo Collaborative. Zwiegelaar is co-inventor of 2 patent families relating to AzarGen’s lead therapeutic candidate and synthetic promoter technology.ĭr. Zwiegelaar currently manages the product development as well as day to day business operations. After several years in keeping the business alive during his PhD studies and running an IT and web-design business on the side to pay his bills, the company was successful in obtaining significant seed funding, allowing him to pursue his lifelong passion.
In his own words – “I was always dreaming of pursuing my passion for technology and science by taking my ideas to market and delivering exceptional products that will change the world.” Starting out with AzarGen directly after completion of his Masters studies at Stellenbosch University he set out to pursue that dream and make it a reality. He has a keen interest in business and has been involved in several ventures from an early age, which contributed to develop him as an entrepreneur. Zwieglaar is co-founder and COO of AzarGen.
After completing a productive internship, as a business analyst at a business consultancy, he decided to combine his passion for science with business to become a biotech entrepreneur.ĭr. Venter is co-inventor of 2 patent families relating to AzarGen’s lead therapeutic candidate and synthetic promoter technology.
He has presented papers at several national and international conferences and authored or co-authored 17 research, book chapter and review articles in biotechnology and medical genetics. During his postdoc fellowship in human genetics, he attracted funding and served as project leader of a Self-Initiated SA-MRC (South African Medical Research Council)-project. He was part of the first group of postdoctoral fellows in South Africa to receive the National Research Foundation Innovation-Fund Postdoc Bursary in 2005-2006. He conducted genetic research at Stellenbosch University, completing two postdoctoral fellowships (in plant biotechnology and human genetics respectively) and worked as a contract researcher and lecturer. He has a PhD in Plant Biotechnology from Stellenbosch University, and he completed an Executive MBA program from the University of Cape Town's Graduate School of Business.
0 kommentar(er)
